TWi Biotechnology, Inc. (TPEX:6610)

Market Cap	5.45B +465.1%
Revenue (ttm)	n/a
Net Income	-202.37M
EPS	-1.84
Shares Out	203.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	229,986
Open	27.60
Previous Close	27.50
Day's Range	25.95 - 27.60
52-Week Range	10.60 - 40.85
Beta	0.97
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About TWi Biotechnology

TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial for the treatment of vitiligo and preclinical stage for the treatment of atopic dermatitis, as well as granuloma annulare and rare autoimmune skin diseas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 27
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6610

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error